Keytruda Plus Chemotherapy Extends Survival in NSCLC Patients Lacking PD-L1 Expression

Sep 10, 2019

|

NEW YORK -- Pooled analysis from three studies suggests there may be a survival advantage for advanced non-small cell lung cancer patients who lack PD-L1 expression and receive pembrolizumab (Merck's Keytruda) and chemotherapy as a front-line option.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Menu

Keytruda Plus Chemotherapy Extends Survival in NSCLC Patients Lacking PD-L1 Expression

To read the full story....

Breaking News

Merck's Keytruda sBLA for Tumor Mutation Burden-High Cancer Patients Accepted by FDA

Sequencing, Molecular Tumor Board Enable Precision Therapy for GI Cancer Patients, Study Shows

Genetic Testing Challenges in Oncology: Patient With BRCA1 VUS Has Prophylactic Surgery

European Commission Approves Takeda's Alunbrig for First-Line ALK-positive Lung Cancer

Myriad Genetics BRCA Test to be Reimbursed in Japan

NOTCH Mutations Potentially Predictive for Immunotherapy Response in Lung Cancer

Featured White Papers

What's Popular?

Myriad Genetics BRCA Test to be Reimbursed in Japan

Adventist Health, CancerIQ Collaboration Identifying More Patients for Guidelines-Supported Genetic Testing

Blood-Based Genetic Risk Score Shows Promise for Prostate Cancer Drug Response, Survival Prediction

Merck's Keytruda sBLA for Tumor Mutation Burden-High Cancer Patients Accepted by FDA

European Commission Approves Takeda's Alunbrig for First-Line ALK-positive Lung Cancer

Sponsorships